Description
Ketotifen 1 mg Sopharma — ketotifen from Sopharma at 1 mg. H1-receptor antagonist and mast-cell stabiliser. Reverses beta-2 receptor downregulation — enables continuous clenbuterol use.
Key Benefits
- β2-agonist — standard asthma bronchodilator
- Modest thermogenic and fat-mobilising effects
- Milder than clenbuterol; shorter half-life
- Oral or inhaled; performance use typically oral
- 2-on / 2-off cycling recommended like clenbuterol
- Each unit dosed at 1 mg — see Recommended Dosage below for protocol-specific intake
How It Works
Selective β2-adrenergic agonist. Bronchodilation primary effect; metabolic effects (increased cAMP → lipolysis) secondary. Milder thermogenic profile than clenbuterol due to shorter half-life.
Pharmacokinetics
Plasma half-life approximately 4–6 hours. Multiple daily doses required for continuous effect. Oral bioavailability ~50%.
Potential Side Effects
Tremors, tachycardia, headache, muscle cramps (taurine supplementation helps). Tolerance develops — hence 2-on / 2-off cycling. Cardiac hypertrophy concern on long runs.
Cycle & Stacking Guide
Cutting-phase compound, 2-on / 2-off cycling. Milder alternative to clenbuterol. Avoid late-day dosing (insomnia).
Manufacturer Notes
Sopharma is a Bulgarian pharmaceutical producer with over 80 years of history. Their products are GMP-compliant and dispensed through European pharmacy channels.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.